Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Maravai Lifesciences (MRVI) to $2 from $3 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results where revenue beat and guidance is maintained for 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVI:
- Maravai LifeSciences Reports Q1 2025 Financial Results
- Maravai Lifesciences reports Q1 adjusted EPS (8c), consensus (7c)
- Maravai Lifesciences sees FY25 revenue $185M-$205M, consensus $192.75M
- MRVI Upcoming Earnings Report: What to Expect?
- MRVI Lawsuit Alert! Class Action Lawsuit Against Maravai Lifesciences Holdings